UniQure NV says the U.S. Food and Drug Administration (FDA) has reversed its position on the company’s experimental Huntington’s disease gene therapy, allowing it to pursue U.S. approval without first completing an additional new study. Multiple outlets report that the FDA previously opposed the proposed path for review following concerns tied to clinical trial data and the timing of further evidence. After the latest FDA decision, UniQure can submit for approval, a shift described as a reversal following a public dispute between the company and FDA leaders. The change is portrayed as significant for a closely watched therapy in Huntington’s disease, where treatment options remain limited. UniQure’s shares rise after the announcement, reflecting market expectations that the company’s regulatory pathway has improved. The company’s next steps include preparing an application for FDA consideration, while the FDA’s decision changes the immediate requirements for additional study work. The reports agree on the core facts: the FDA reverses its stance, UniQure is cleared to seek approval for its Huntington’s therapy, and the decision follows an earlier clash with the agency.
UniQure cleared to seek FDA approval for Huntington’s gene therapy after FDA reversal
UniQure NV says the U.S. Food and Drug Administration (FDA) has reversed its position on the company’s experimental Huntington’s disease gene therapy, allowing it to pursue U.S. approval without first...
- UniQure NV says the FDA reverses its prior stance on its Huntington’s disease gene therapy.
- The reversal allows UniQure to seek U.S. approval without conducting a new study first.
- UniQure had previously faced opposition from the FDA following a dispute involving the application pathway and clinical trial data.
- UniQure announces the change and plans next steps toward submitting an FDA approval request.
- UniQure shares increase following the announcement.
The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.
13 hours agoThe FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its maker.
18 hours agoUniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.
18 hours ago
Charity Imix says it supplied migrants for BBC Question Time debate in Dover
Multiple reports focus on a BBC Question Time “Immigration Special” debate held in Dover in December and the involvement...
DHS transfers detainees from Florida’s “Alligator Alcatraz” detention facility
U.S. Department of Homeland Security officials and ICE say all detainees have been moved out of the “Alligator Alcatraz”...
Alex Eala advances past Frech but exits Italian Open in singles and doubles
Alex Eala’s 2026 Italian Open run in Rome ends after she reaches the singles Round of 32 and also plays doubles. In her...